SOURCE: CNS Response

CNS Response

February 18, 2011 10:05 ET

The Journal of Psychiatric Research Features Breakthrough Study Indicating CNS Response's Referenced-EEG® Enables Physicians to Significantly Improve Success Rates in Treating Depression

Success Rate of 65 Percent Using CNS Response's Online Reference Database, Referenced-EEG, for Treatment-Resistant Depression, Compared to 39 Percent in Control Group; Study Article Selected for 50th Anniversary Issue of the Journal of Psychiatric Research

ALISO VIEJO, CA--(Marketwire - February 18, 2011) - A breakthrough study by CNS Response, Inc. (OTCBB: CNSO), featured in the 50th anniversary issue of the Journal of Psychiatric Research, reveals that physicians using CNS's Referenced-EEG® (rEEG), an online reference database, were able to significantly improve their success in treating patients with depression, including patients with treatment-resistant depression. In the 12-week depression study conducted at 12 medical sites, including Harvard, Stanford, Rush and Cornell, physicians achieved a 65 percent success rate in treating patients with depression, compared to a 39 percent success rate in the control group. These results were highly statistically significant.

The subjects in the study, selected through a randomized process, had failed an average of four previous treatments for depression. "To achieve a 65 percent success rate in patients who have already endured four unsuccessful medication treatments is remarkable," said CNS Response CEO George Carpenter. "As our fourth controlled trial and one of 22 medication response trials using EEG neurometrics, this clinical trial contributes to a growing body of evidence that neurometric markers based on EEG can provide clinically useful information."

"Depression, especially treatment-resistant depression, is a major concern for patients and their families, as well as physicians, employers and insurance providers," said one of the study's co-authors, Corey Goldstein, M.D., Department of Psychiatry at Rush University Medical Center in Chicago. "One in three people with depression fail to improve with standard antidepressant therapy and, on average, can spend several years finding the right medicine. As shown in this study, the use of Referenced-EEG appears to hold significant promise as an information tool for physicians by identifying more efficacious patient-specific medications."

Today, most physicians in other disciplines are able to base their treatment recommendations on objective data gathered from EKGs, MRIs, CT scans, blood tests and similar procedures. However, broadly speaking, such advances have not previously been available to medical professionals treating mental illness. Developed by CNS Response, Referenced-EEG provides objective, personalized, statistical data on a patient's neurophysiology. 

"This study represents a breakthrough for patients suffering from depression, and their families, as well as for the health care industry, where depression alone costs U.S. employers upwards of $83 billion annually," said Carpenter. "We expect to further show the efficacy of rEEG to assist physicians in successfully treating other areas of mental health in addition to depression, thereby improving the overall well-being of patients suffering from mental health issues."

What this means for patients
Finding the right medication for an individual patient suffering from mental health issues is one of the biggest challenges facing medical professionals. Medications affect everyone differently, and with over 130 psychotropic medications to choose from, it is difficult for physicians to know which regimen is best. As a result, the dominant treatment approach is trial-and-error. This study suggests that Referenced-EEG can be an easy, relatively inexpensive tool that can assist prescribers in personalizing therapies and reducing trial and error. For patients, this means a significantly shorter time to feel relief, thereby reducing their suffering and costs. 

The study included 114 patients and was conducted across 12 medical sites, including Harvard, Stanford, Cornell, Rush, UCI School of Medicine and others. The article, "The use of referenced-EEG (rEEG) in assisting medication selection in the treatment of depression," is available in its entirety in the 50th anniversary edition of the Journal of Psychiatric Research

About CNS Response
CNS Response develops reference data and analytic tools for clinicians and researchers, using a novel neurometric database called Referenced-EEG (rEEG). Developed by physicians as a platform to exchange objective, neurophysiology-based data on medication response, physicians using rEEG in clinical trials have consistently reduced their use of trial and error pharmacotherapy. To read more about the benefits of this patented technology for patients, physicians and payers, please visit the CNS Response website, www.cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contact Information

  • Investor Relations:
    Marty Tullio
    Managing Partner
    McCloud Communications, LLC
    949.553.9748
    Email Contact

    Media Relations:
    Joyce Johannson
    Johannson Communications
    612.927.4543 (office); 612.845.3080 (cell)
    Email Contact